Comparison of Patient-Controlled Epidural Analgesia with Intravenous Patient-Controlled Analgesia on Postoperative Pain Control after Major Gynecologic Oncologic Surgery-A Randomized controlled clinical trial

Comparison of Postoperative Pain after Gynecologic Oncologic Surgery Epidural and Intravenous

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013071411700N2

Enrollment

Registered

2013-08-29

Start date

2012-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain Control after Gynecologic Oncologic Surgery. Malignant neoplasms of female genital organs

Interventions

Intervention 1: After surgery, In recovery room for group one (IPCA) or which group that will receive intra venous PCA, analgesic will be infused, which contain 300 µg (6ml) fentanyl, 200mg (4ml) pet

Treatment - Drugs

After surgery, In recovery room for group one (IPCA) or which group that will receive intra venous PCA, analgesic will be infused, which contain 300 µg (6ml) fentanyl, 200mg (4ml) petidine and 8mg(2m

Group 2 PCEA will receive epidural catheter from L3-L4 interspaces and only test dose(lidocaine 1.5% 3-4 ml and Epinephrine 1/200000) will be administrated. Group 2 will receive Bupivacaine 0.5% 100

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women’s with gynecologic Oncologic Surgery in the operation list of Alzahra Hospital; Women’s with ASA class I and II; patients who wannt to contribute in the study Exclusion criteria: Women’s with ASA class III or higher; Severe cardiovascular diseases; Epidural anesthesia contraindications;Coagulation disorders or antiquagulant drugs using with therapeutic dose; Spin anomalies; Sepsis; Hypovolemic shock

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Postoperative analgesia. Timepoint: Postoperative 2, 4, 6, 8, 12, 24 and 36 hours. Method of measurement: Severity os pain with Visual Analoge Scale(VAS).	—

Secondary

Measure	Time frame
Sedation. Timepoint: Posoperative 4, 6, 8, 12, 24, 36 hours. Method of measurement: Modified Ramsy sedation scale.;Patient's satisfaction. Timepoint: On the fifth day postoperative. Method of measurement: Score according to postoperative analgesia (nil = 0;.;Nausea and vomiting. Timepoint: Postoperative 2, 4, 6, 8, 12, 24, 36 hours. Method of measurement: Severity of Nausea and vomiting with Belville scorhng.	—

Measure

Time frame

Sedation. Timepoint: Posoperative 4, 6, 8, 12, 24, 36 hours. Method of measurement: Modified Ramsy sedation scale.;Patient's satisfaction. Timepoint: On the fifth day postoperative. Method of measurement: Score according to postoperative analgesia (nil = 0;.;Nausea and vomiting. Timepoint: Postoperative 2, 4, 6, 8, 12, 24, 36 hours. Method of measurement: Severity of Nausea and vomiting with Belville scorhng.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farnaz Moslemi

Women's Reproductive Health Research Center, Tabriz University of Medical Sciences

moslemi_fa@yahoo.com+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026